Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
179.45B
Market cap179.45B
Price-Earnings ratio
-54.49
Price-Earnings ratio-54.49
Dividend yield
2.25%
Dividend yield2.25%
Average volume
5.24M
Average volume5.24M
High today
$148.02
High today$148.02
Low today
$144.00
Low today$144.00
Open price
$147.62
Open price$147.62
Volume
4.80M
Volume4.80M
52 Week high
$157.29
52 Week high$157.29
52 Week low
$109.66
52 Week low$109.66

Stock Snapshot

The current Gilead Sciences(GILD) stock price is $144.92, with a market capitalization of 179.45B. The stock trades at a price-to-earnings (P/E) ratio of -54.49 and offers a dividend yield of 2.25%.

During the trading session on 2026-10-03, Gilead Sciences(GILD) shares reached a daily high of $148.02 and a low of $144.00. At a current price of $144.92, the stock is +0.6% higher than the low and still -2.1% under the high.

Trading activity shows a volume of 4.8M, compared to an average daily volume of 5.24M.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $109.66.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $109.66.

GILD News

Zacks 1d
Gilead Sciences Stock Sinks As Market Gains: What You Should Know

In the latest close session, Gilead Sciences (GILD Quick QuoteGILD - Free Report) was down 1.87% at $144.74. The stock's change was less than the S&P 500'...

Gilead Sciences Stock Sinks As Market Gains: What You Should Know
MarketWatch 1d
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch

...

Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Zacks 3d
Gilead Sciences Declines More Than Market: Some Information for Investors

Gilead Sciences (GILD Quick QuoteGILD - Free Report) ended the recent trading session at $149.45, demonstrating a -1.21% change from the preceding day's c...

Gilead Sciences Declines More Than Market: Some Information for Investors

Analyst ratings

77%

of 30 ratings
Buy
76.7%
Hold
20%
Sell
3.3%

More GILD News

Simply Wall St 4d
Gilead Sciences Tests Its Multi Platform Story On Questions Around Valuation

Gilead Sciences (GILD) is back in focus after securing a $2.5 million federal grant with research partners to pursue oral treatments for mosquito-borne flavivir...

Gilead Sciences Tests Its Multi Platform Story On Questions Around Valuation

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.